Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Invivyd ( (IVVD) ).
On May 19, 2026, Invivyd, Inc. held its Annual Meeting of Stockholders, at which shareholders elected directors Tamsin Berry, Paul B. Bolno, M.D., Marc Elia, Terrance McGuire, Kevin F. McLaughlin and Ajay Royan to one-year terms ending at the 2027 annual meeting. The voting results, with large majorities in favor of each nominee and significant broker non-votes, reaffirmed the company’s existing board leadership and governance structure for the coming year.
At the same May 19, 2026 meeting, stockholders also ratified the appointment of PricewaterhouseCoopers LLP as Invivyd’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with an overwhelming vote in favor and minimal opposition. This ratification supports continuity in Invivyd’s financial oversight and audit practices, providing stability and assurance for investors and other stakeholders regarding the company’s reporting and compliance processes.
The most recent analyst rating on (IVVD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.
Spark’s Take on IVVD Stock
According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.
The score is held down primarily by weak financial performance (large ongoing losses and heavy cash burn despite strong gross margins) and bearish technical trend (below major moving averages). Offsetting these, the latest earnings call indicates operational and clinical momentum (pivotal trial progress, improved monitoring requirements, and PEMGARDA growth), while valuation signals are constrained by negative earnings and no dividend support.
To see Spark’s full report on IVVD stock, click here.
More about Invivyd
Invivyd, Inc. is a biotechnology company, as indicated by its structure and governance, operating with a public stockholder base and a board of directors elected annually at its shareholder meetings. The company engages an independent registered public accounting firm to audit its financial statements, reflecting its participation in regulated public capital markets and compliance-focused corporate operations.
Average Trading Volume: 2,915,402
Technical Sentiment Signal: Sell
Current Market Cap: $356.5M
See more insights into IVVD stock on TipRanks’ Stock Analysis page.